Biomimetic Strategies To Treat Traumatic Brain Injury by Leveraging Fibrinogen

Author/Creator ORCID





Citation of Original Publication

Ashley C. Brown, Erin Lavik, and Sarah E. Stabenfeldt, Biomimetic Strategies To Treat Traumatic Brain Injury by Leveraging Fibrinogen, Bioconjugate Chemistry 2019 30 (7), 1951-1956 DOI: 10.1021/acs.bioconjchem.9b00360


This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Access to this item will begin on 2020-06-27
This document is the Accepted Manuscript version of a Published Work that appeared in final form in Bioconjugate Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see:


There were over 27 million new cases of traumatic brain injuries (TBIs) in 2016 across the globe. TBIs are often part of complicated trauma scenarios and may not be diagnosed initially because the primary clinical focus is on stabilizing the patient. Interventions used to stabilize trauma patients may inadvertently impact the outcomes of TBIs. Recently, there has been a strong interest in the trauma community toward administrating fibrinogen-containing solutions intravenously to help stabilize trauma patients. While this interventional shift may benefit general trauma scenarios, fibrinogen is associated with potentially deleterious effects for TBIs. Here, we deconstruct what components of fibrinogen may be beneficial as well as potentially harmful following TBI and extrapolate this to biomimetic approaches to treat bleeding and trauma that may also lead to better outcomes following TBI.